Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
May 28, 2024 08:45 ET
|
Aprea Therapeutics
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial...
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
May 14, 2024 08:30 ET
|
Aprea Therapeutics
U.S. FDA cleared IND for APR-1051, a highly selective and potentially best-in-class oral WEE1 inhibitor; Company plans to initiate Phase 1 ACESOT-1051 clinical trial in June 2024 First-in-class...
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
May 13, 2024 16:01 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through...
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 02, 2024 09:15 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology...
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
April 10, 2024 12:00 ET
|
Aprea Therapeutics
Pre-clinical findings underscore the potential of APR-1051, a next-generation WEE1 kinase inhibitor, to be a well-tolerated and effective treatment for Cyclin E-overexpressing cancers IND for...
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
March 26, 2024 07:45 ET
|
Aprea Therapeutics
First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly...
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
March 11, 2024 08:30 ET
|
Aprea Therapeutics
Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors $16.0 million in upfront gross proceeds with the potential to receive up to an...
Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers
March 11, 2024 08:29 ET
|
Aprea Therapeutics
Company plans to initiate Phase 1 ACESOT-1051 (A Multi-Center Evaluation of WEE1 Inhibitor in Patients with Advanced Solid Tumors, APR-1051) clinical trial evaluating, highly selective, oral WEE1...
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
March 05, 2024 16:45 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., March 05, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology...
Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor
February 06, 2024 08:01 ET
|
Aprea Therapeutics
DOYLESTOWN, Pa., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology...